425 related articles for article (PubMed ID: 26007293)
1. MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.
Sondermann A; Andreghetto FM; Moulatlet AC; da Silva Victor E; de Castro MG; Nunes FD; Brandão LG; Severino P
Clin Exp Metastasis; 2015 Aug; 32(6):521-30. PubMed ID: 26007293
[TBL] [Abstract][Full Text] [Related]
2. MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer.
Dai L; Wang Y; Chen L; Zheng J; Li J; Wu X
World J Surg Oncol; 2017 Jan; 15(1):11. PubMed ID: 28061868
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.
Lee JC; Zhao JT; Clifton-Bligh RJ; Gill A; Gundara JS; Ip JC; Glover A; Sywak MS; Delbridge LW; Robinson BG; Sidhu SB
Cancer; 2013 Dec; 119(24):4358-65. PubMed ID: 24301304
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of miR-146b expression and its functional role in papillary thyroid carcinoma.
Chou CK; Yang KD; Chou FF; Huang CC; Lan YW; Lee YF; Kang HY; Liu RT
J Clin Endocrinol Metab; 2013 Feb; 98(2):E196-205. PubMed ID: 23264400
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma.
Yip L; Kelly L; Shuai Y; Armstrong MJ; Nikiforov YE; Carty SE; Nikiforova MN
Ann Surg Oncol; 2011 Jul; 18(7):2035-41. PubMed ID: 21537871
[TBL] [Abstract][Full Text] [Related]
6. Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.
Todorović L; Stanojević B; Mandušić V; Petrović N; Živaljević V; Paunović I; Diklić A; Saenko V; Yamashita S
Med Oncol; 2018 Jan; 35(2):17. PubMed ID: 29340905
[TBL] [Abstract][Full Text] [Related]
7. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
Qiu Z; Li H; Wang J; Sun C
Oncol Rep; 2017 Nov; 38(5):2735-2740. PubMed ID: 29048684
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck.
Lee CW; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
Ann Surg Oncol; 2015 Jan; 22(1):117-24. PubMed ID: 25034816
[TBL] [Abstract][Full Text] [Related]
9. [Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features].
Jiang XL; Zhang H; Chen YL; Peng L
Zhonghua Bing Li Xue Za Zhi; 2017 Mar; 46(3):160-165. PubMed ID: 28297755
[No Abstract] [Full Text] [Related]
10. Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma.
Yang Z; Yuan Z; Fan Y; Deng X; Zheng Q
Mol Med Rep; 2013 Nov; 8(5):1353-8. PubMed ID: 24064622
[TBL] [Abstract][Full Text] [Related]
11. Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma.
Sun M; Fang S; Li W; Li C; Wang L; Wang F; Wang Y
Cancer Biomark; 2015; 15(1):33-40. PubMed ID: 25524940
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma.
Chen YT; Kitabayashi N; Zhou XK; Fahey TJ; Scognamiglio T
Mod Pathol; 2008 Sep; 21(9):1139-46. PubMed ID: 18587330
[TBL] [Abstract][Full Text] [Related]
13. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
[TBL] [Abstract][Full Text] [Related]
14. In Situ Hybridization Analysis of miR-146b-5p and miR-21 in Thyroid Nodules: Diagnostic Implications.
Guo Z; Hardin H; Montemayor-Garcia C; Asioli S; Righi A; Maletta F; Sapino A; Lloyd RV
Endocr Pathol; 2015 May; 26(2):157-63. PubMed ID: 25771986
[TBL] [Abstract][Full Text] [Related]
15. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
16. Papillary thyroid cancer: controversies in the management of neck metastasis.
Davidson HC; Park BJ; Johnson JT
Laryngoscope; 2008 Dec; 118(12):2161-5. PubMed ID: 19029855
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
18. A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma.
Nadal E; Zhong J; Lin J; Reddy RM; Ramnath N; Orringer MB; Chang AC; Beer DG; Chen G
Clin Cancer Res; 2014 Jun; 20(12):3107-17. PubMed ID: 24833665
[TBL] [Abstract][Full Text] [Related]
19. Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas.
Fehér LZ; Pocsay G; Krenács L; Zvara A; Bagdi E; Pocsay R; Lukács G; Győry F; Gazdag A; Tarkó E; Puskás LG
Pathol Oncol Res; 2012 Apr; 18(2):449-58. PubMed ID: 22161024
[TBL] [Abstract][Full Text] [Related]
20. Central lymph node metastasis of unilateral papillary thyroid carcinoma: patterns and factors predictive of nodal metastasis, morbidity, and recurrence.
Roh JL; Kim JM; Park CI
Ann Surg Oncol; 2011 Aug; 18(8):2245-50. PubMed ID: 21327454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
